The full archive
Every article we've published, newest first. Search by title or summary to find what you're looking for.
Senator Rand Paul's new Hemp Safety Enforcement Act offers states a constitutional escape hatch from a federal ban that could wipe out a $28 billion industry on November 12. Inside the decade-long fight — the Kentucky civil war with McConnell, the arbitrary 0.3% number, and the strange-bedfellows coalition trying to end hemp.
Nine months after being sworn in as DEA Administrator, Terry Cole has let the Schedule III rulemaking sit exactly where his predecessor left it: nowhere. His career, his public statements, and the agency's 50-year track record tell you everything about why.
From a quiet 2013 bill by a Colorado Democrat to seven House passages, a historic 2023 Senate committee vote, and a Trump-era rescheduling collision that pushed it off the agenda — the full story of how Congress has spent more than a decade trying, and failing, to let legal cannabis businesses open a checking account.
The federal lawsuit threatening Medicare's new CBD pilot just got more complicated. An amended complaint, new plaintiffs with concrete competitive-injury claims, and a new May 1 hearing reset the entire case.
Ron DeSantis championed medical marijuana, protected the hemp market, and crushed recreational legalization — all while cashing checks from every side. A Green Brief investigation follows the money.
From a 1990 Miami luncheon calling drug enforcement 'a joke' to a 2025 rescheduling executive order his own DOJ is undermining — a definitive history of America's most contradictory president and the plant he can't quite figure out.
Mitch McConnell's 2018 hemp language accidentally birthed a $28 billion unregulated THC market. On November 12, 2026, the loophole closes — and a seven-year experiment in chemical improvisation, gas-station gummies, and regulatory drift finally meets its deadline.
Six days after Trump fired Pam Bondi, acting AG Todd Blanche inherited a stalled rescheduling process — and a directive to finish it. Here's who he is, what he's said about cannabis, and what to watch next.
Pam Bondi's decade-long war against marijuana ended not with a policy reversal, but with a pink slip. Her cannabis record tells the real story.
A complete history of how one agency kept a plant in the same legal category as heroin — against the advice of its own judges, federal scientists, and the American public.
A 3,000-year-old mistranslation, a Polish anthropologist's radical theory, and an archaeological bombshell in the Negev desert are rewriting the relationship between Christianity and cannabis.
New research confirms that the euphoria of intense exercise is driven primarily by the body's own cannabinoid system, rewriting a decades-old assumption about endorphins.
A controlled trial at Johns Hopkins found that specific terpene profiles changed the subjective experience and neurological response to THC, lending scientific weight to a long-debated cannabis theory.
Published in JAMA Internal Medicine, the retrospective study of 15,000 veterans across 12 states found significant and sustained reductions in opioid use after medical cannabis enrollment.
The review analyzed 50 randomized controlled trials and found that cannabinoids may reduce chronic pain intensity by a small but meaningful amount — while flagging high rates of adverse events.
A survey of state-level social equity programs reveals a pattern: ambitious promises at launch, followed by bureaucratic delays, underfunding, and capture by well-financed operators.
A deep dive into the tax provision that prevents marijuana businesses from deducting ordinary expenses, and the massive financial implications of a move to Schedule III.
The rule replaces the delta-9-only standard from the 2018 Farm Bill with a total-THC measurement, effectively banning most intoxicating hemp products at the federal level.
Published in the International Journal of Molecular Sciences, new research points to potential food safety and antimicrobial applications of cannabidiol beyond traditional therapeutic uses.
New rules from the Department of State Health Services took effect March 31, prohibiting the sale of intoxicating hemp flower and vaporizer products statewide as part of a broader federal crackdown.
Published in The Lancet Psychiatry, the systematic review examined hundreds of studies and found insufficient evidence to support therapeutic claims for cannabinoid treatments of mental health conditions.
Dispensaries reported over 1.7 million ounces of smokable marijuana sold through March, while organizers push for a new recreational ballot measure after the 2024 initiative failed.
Despite Trump's December executive order directing expedited rescheduling, the DEA has yet to appoint a new administrative law judge. Congressional opposition from 48 GOP lawmakers adds uncertainty to the timeline.
The CMS Innovation Center launched its Substance Access Beneficiary Engagement Incentive on April 1, allowing select Medicare patients to receive up to $500 in physician-supervised, hemp-derived CBD products annually. But an April 20 court date could shut it down before it scales.